Last reviewed · How we verify
SAMA
Sama is a small molecule that works by interacting with a specific biological target to produce a therapeutic effect.
Sama is a small molecule developed by Novartis Pharmaceuticals and currently owned by Lantheus Medical. Unfortunately, there is limited information available on its target, drug class, and approved indications. As it is off-patent, there are no active Orange Book patents. The commercial status of Sama is not well-documented, and its safety considerations are unknown. Further research is needed to understand its clinical applications and pharmacological properties.
At a glance
| Generic name | SAMA |
|---|---|
| Sponsor | Lantheus Medical |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Mechanism of action
Imagine Sama as a key that fits into a lock on a cell. When it binds to the lock, it triggers a series of events that ultimately lead to a desired outcome, such as treating a disease or condition. This process is complex and involves many molecular interactions, but essentially, Sama helps to restore balance to the body's natural processes.
Approved indications
- Pain due to Osteoblastic Bone Metastasis
Common side effects
Key clinical trials
- Effects of Pranayama Breathing Technique on Stress Level, Sleep Quality, and Quality of Life Among Older Adults (NA)
- Comparison of Breathing Yoga and Progressive Muscle Relaxation Techniques After Transplantation (NA)
- The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients (PHASE4)
- Effectiveness of Electrical Pudendal Nerve Stimulation for Neurogenic Lower Urinary Tract Dysfunction in Pediatric Tethered Cord Syndrome Post-Surgery (NA)
- Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors (PHASE1,PHASE2)
- Short Acting Agents Vs Long Acting in Frequent Excerbator COPD Patients (EARLY_PHASE1)
- The Effect of Relaxing Breathing Exercise Applied to Patients Before Bone Marrow Biopsy on Vital Signs, Pain and Anxiety Levels (NA)
- Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SAMA CI brief — competitive landscape report
- SAMA updates RSS · CI watch RSS
- Lantheus Medical portfolio CI